The MFT Haemoglobinopathy Diagnostic Service is offered to all at risk of sickle cell disease or thalassaemia. The Haemoglobinopathy Laboratory carries out first and second line confirmatory screening abnormal haemoglobin variants and thalassaemia, we also undertake confirmatory testing for the Newborn Screening Laboratory at MFT and for external laboratories.
More information on laboratory services including turnaround times and reference ranges available in the laboratory user guide.
All positive haemoglobinopathy screening results are reviewed at the weekly Multi-Disciplinary Team meetings held with Clinical, Scientific, Nursing and Specialist Counsellors from across MFT, the genetics service and the Manchester Sickle Cell and Thalassaemia Centre (including adults and paediatric specialists). The laboratory team work to quality standards set by, and report to, the National Screening Programme for Antenatal Haemoglobinopathy Screening.
Available to providers in England as described in the National Genomic Test Directory for rare and inherited disease. See details and eligibility criteria.
See information including the guidelines for haemoglobinopathy genetic testing and associated referral forms and a genetic testing consent form.
Services, policies and procedures for the treatment of patients with sickle cell disease or thalassaemia can be found in Clinical Haematology.
(Last reviewed April 2021)